Rational Design of Broad-Spectrum Non-Nucleoside Reverse Transcriptase Inhibitors via Pharmacophore-Oriented Generative Artificial Intelligence
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Guided by the pharmacophore-oriented molecular generation platform PhoreGen, we employed rilpivirine (RPV) as a lead compound to generate 300 structurally diverse analogs that preserve key pharmacophoric features. Subsequent drug-likeness evaluation, molecular docking score, and synthetic feasibility led to the identification of compound No.102 ( A19 ), which displayed potent inhibition activity against WT HIV-1 (EC 50 = 3.15 nM) and low cytotoxicity (CC 50 > 335 μM). Subsequent structure–activity relationship optimization identified A24, which demonstrated robust activity against clinically relevant drug-resistant HIV-1 mutants (EC 50 = 2.07–28.8 nM). Notably, compared to RPV, A24 exhibited significantly reduced cytotoxicity (CC 50 = 82.3 μM vs. 3.98 μM) and enhanced potency against the Y188L (EC 50 = 28.8 nM vs. 79.4 nM) and F227L + V106A (EC 50 = 19.0 nM vs. 81.6 nM) mutants. Pharmacokinetic evaluations revealed that A24 exhibited attenuated CYP enzyme inhibition (IC 50 ≥ 1.88 μM), reduced hERG-related toxicity (IC 50 = 2.633 μM), and improved metabolic stability (human t 1/2 = 39.1 min). Collectively, these favorable properties position A24 as a promising NNRTI for further development.
Fields of Study & Subjects
Computational Drug Discovery Methods
HIV/AIDS drug development and treatment
Synthesis and Characterization of Heterocyclic Compounds
Publication details
- Journal / source
- Journal of Medicinal Chemistry
- Volume
- 69
- Issue
- 7
- Pages
- 8503–8520
- Publication date
- 30 March 2026
- Language
- EN